JP2010512730A - 肺癌の腫瘍マーカーおよび治療標的としてのttk - Google Patents

肺癌の腫瘍マーカーおよび治療標的としてのttk Download PDF

Info

Publication number
JP2010512730A
JP2010512730A JP2009524832A JP2009524832A JP2010512730A JP 2010512730 A JP2010512730 A JP 2010512730A JP 2009524832 A JP2009524832 A JP 2009524832A JP 2009524832 A JP2009524832 A JP 2009524832A JP 2010512730 A JP2010512730 A JP 2010512730A
Authority
JP
Japan
Prior art keywords
seq
ttk
polypeptide
egfr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009524832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512730A5 (https=
Inventor
祐輔 中村
弥太郎 醍醐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2010512730A publication Critical patent/JP2010512730A/ja
Publication of JP2010512730A5 publication Critical patent/JP2010512730A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009524832A 2006-12-13 2007-12-12 肺癌の腫瘍マーカーおよび治療標的としてのttk Withdrawn JP2010512730A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87479106P 2006-12-13 2006-12-13
PCT/JP2007/074359 WO2008072777A2 (en) 2006-12-13 2007-12-12 Ttk as tumor marker and therapeutic target for lung cancer

Publications (2)

Publication Number Publication Date
JP2010512730A true JP2010512730A (ja) 2010-04-30
JP2010512730A5 JP2010512730A5 (https=) 2012-01-19

Family

ID=39332098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524832A Withdrawn JP2010512730A (ja) 2006-12-13 2007-12-12 肺癌の腫瘍マーカーおよび治療標的としてのttk

Country Status (5)

Country Link
US (1) US20100009920A1 (https=)
EP (3) EP2468887A1 (https=)
JP (1) JP2010512730A (https=)
TW (1) TW200831673A (https=)
WO (1) WO2008072777A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501496A (ja) * 2010-10-20 2014-01-23 ユニヴェルシテ ボルドー セガラン 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法
JP2016516669A (ja) * 2013-02-22 2016-06-09 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 転写因子atf5の阻害により腫瘍細胞を阻害するための組成物および方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2459492T3 (es) * 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
ES2339524B1 (es) * 2008-08-28 2011-03-22 Proyecto De Biomedicina Cima, S.L. Nuevo biomarcador como diana terapeutica en cancer de pulmon.
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
US20120021432A1 (en) * 2010-04-16 2012-01-26 Arqule, Inc. Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same
KR101232084B1 (ko) * 2011-10-31 2013-02-08 연세대학교 산학협력단 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 nmd-무관 암 세포 바이오 마커
WO2018152446A2 (en) 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
CN109423517B (zh) * 2017-08-28 2022-08-05 中国医学科学院肿瘤医院 外泌体在肿瘤诊断、治疗和预后评估中的用途
EP3737399B1 (en) 2018-01-03 2023-07-26 Sapience Therapeutics, Inc. Atf5 peptide variants and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンb由来の腫瘍抗原ペプチド
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
US20030045491A1 (en) * 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
CA2438092C (en) * 2001-02-21 2011-08-09 Chiron Corporation Ttk in diagnosis and as a therapeutic target in cancer
CN1612930A (zh) 2001-11-21 2005-05-04 三菱化学株式会社 抑制基因表达的方法
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
PT1581812E (pt) * 2003-01-06 2008-09-22 Wyeth Corp Composições e métodos para diagnóstico e tratamento de cancros do cólon
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20060241072A1 (en) 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
HRP20171010T8 (hr) 2004-08-23 2017-11-03 Sylentis S.A.U. Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
SG156625A1 (en) * 2004-12-08 2009-11-26 Aventis Pharma Inc Method for measuring resistance or sensitivity to docetaxel
EP1856278A2 (en) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
ES2459492T3 (es) * 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501496A (ja) * 2010-10-20 2014-01-23 ユニヴェルシテ ボルドー セガラン 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法
JP2016516669A (ja) * 2013-02-22 2016-06-09 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 転写因子atf5の阻害により腫瘍細胞を阻害するための組成物および方法
US10155796B2 (en) 2013-02-22 2018-12-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5
US10273274B2 (en) 2013-02-22 2019-04-30 The Regents Of The University Of California Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5
US11555057B2 (en) 2013-02-22 2023-01-17 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

Also Published As

Publication number Publication date
EP2468887A1 (en) 2012-06-27
WO2008072777A3 (en) 2008-07-31
EP2468886A1 (en) 2012-06-27
TW200831673A (en) 2008-08-01
US20100009920A1 (en) 2010-01-14
WO2008072777A2 (en) 2008-06-19
EP2102360A2 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
JP2010512730A (ja) 肺癌の腫瘍マーカーおよび治療標的としてのttk
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのprmt1
CN101443022A (zh) 生长刺激蛋白质的用途
US20100184047A1 (en) Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
US20110014615A1 (en) METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
JP6064231B2 (ja) がん治療および診断のための標的遺伝子としてのsuv39h2
EP1915622A2 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2012501163A (ja) がんの治療および診断用の標的遺伝子としてのc12orf48
CN101528768A (zh) 与乳腺癌相关的基因和多肽
WO2010023838A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
US20110070245A1 (en) Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
WO2009113295A1 (en) C2orf18 as target gene for cancer therapy and diagnosis
WO2012023284A1 (en) Lhx4 as a target gene for cancer therapy and diagnosis
US20110313018A1 (en) Cancer related gene, lgn/gpsm2
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
JP2010500004A (ja) 前立腺癌関連遺伝子styk1
JP2009505631A (ja) 癌関連遺伝子rasgef1a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111118

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120718